In-hospital pulse pressure variability: A novel marker of cardiovascular risk among patients with coronary artery disease undergoing percutaneous coronary intervention?
作者信息
Nadruz Wilson
机构信息
Department of Internal Medicine, School of Medical Sciences, State University of Campinas, SP, Brazil.
出版信息
Int J Cardiol Heart Vasc. 2024 Jun 15;53:101445. doi: 10.1016/j.ijcha.2024.101445. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
In-hospital pulse pressure variability: A novel marker of cardiovascular risk among patients with coronary artery disease undergoing percutaneous coronary intervention?住院期间脉压变异性：经皮冠状动脉介入治疗的冠心病患者心血管风险的新标志物？
Int J Cardiol Heart Vasc. 2024 Jun 15;53:101445. doi: 10.1016/j.ijcha.2024.101445. eCollection 2024 Aug.
2
Association between visit-to-visit blood pressure variability and adverse events in coronary artery disease patients after coronary intervention.经皮冠状动脉介入治疗后冠心病患者血压变异性与不良事件的关系。
J Clin Hypertens (Greenwich). 2022 Oct;24(10):1327-1338. doi: 10.1111/jch.14565. Epub 2022 Sep 12.
3
Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention.经皮冠状动脉介入治疗术前血压对长期预后的影响。
J Am Coll Cardiol. 2019 Jun 11;73(22):2846-2855. doi: 10.1016/j.jacc.2019.03.493.
4
In-Hospital Blood Pressure Variability: A Novel Prognostic Marker of Renal Function Decline and Cardiovascular Events in Patients with Coronary Artery Disease.住院期间血压变异性：冠心病患者肾功能下降和心血管事件的新预后标志物。
Kidney Blood Press Res. 2020;45(5):748-757. doi: 10.1159/000509291. Epub 2020 Oct 7.
5
Major adverse cardiovascular events in patients undergoing percutaneous coronary intervention or coronary artery bypass graft with underlying chronic kidney disease.患有基础慢性肾脏病的患者在接受经皮冠状动脉介入治疗或冠状动脉旁路移植术时发生的主要不良心血管事件。
J Pak Med Assoc. 2020 Nov;70(11):1901-1907. doi: 10.5455/JPMA.22790.
6
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.接受经皮冠状动脉介入治疗的稳定型冠状动脉疾病患者中，血小板对氯吡格雷反应的变异性与不良心血管事件无关。
Eur J Clin Pharmacol. 2017 Sep;73(9):1085-1094. doi: 10.1007/s00228-017-2271-x. Epub 2017 Jun 6.
7
Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease.脉压在 2 型糖尿病合并冠状动脉疾病患者心脏策略选择中的作用。
Int J Cardiol. 2018 Dec 15;273:1-7. doi: 10.1016/j.ijcard.2018.07.143. Epub 2018 Aug 2.
8
Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention.尿酸变异性与经皮冠状动脉介入治疗的冠心病患者未来临床结局的关系。
Atherosclerosis. 2020 Mar;297:40-46. doi: 10.1016/j.atherosclerosis.2020.01.025. Epub 2020 Jan 30.
9
Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention.接受经皮冠状动脉介入治疗的无保护左主干或多支冠状动脉疾病患者的手术禁忌和死亡率
Circulation. 2014 Dec 23;130(25):2295-301. doi: 10.1161/CIRCULATIONAHA.114.011541. Epub 2014 Nov 12.
10
Outcomes Following Primary Percutaneous Coronary Intervention in Patients With Previous Coronary Artery Bypass Surgery.经皮冠状动脉介入治疗在既往冠状动脉旁路移植术患者中的结果。
Circ Cardiovasc Interv. 2016 Apr;9(4):e003151. doi: 10.1161/CIRCINTERVENTIONS.115.003151.
本文引用的文献
1
Impact of the number of modifiable risk factors on clinical outcomes after percutaneous coronary intervention: An analysis from the e-Ultimaster registry.经皮冠状动脉介入治疗后可改变危险因素数量对临床结局的影响：来自e-Ultimaster注册研究的分析
Int J Cardiol Heart Vasc. 2024 Feb 26;51:101370. doi: 10.1016/j.ijcha.2024.101370. eCollection 2024 Apr.
2
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).2023ESH 动脉高血压管理指南 欧洲高血压学会动脉高血压管理工作组：得到国际高血压学会 (ISH) 和欧洲肾脏协会 (ERA) 的认可。
J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26.
3
Predictive ability of visit-to-visit blood pressure indices for adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry.非瓣膜性心房颤动患者就诊间血压指标对不良事件的预测能力：J-RHYTHM注册研究的亚分析
Int J Cardiol Heart Vasc. 2023 May 6;46:101216. doi: 10.1016/j.ijcha.2023.101216. eCollection 2023 Jun.
4
Vascular stiffening and endothelial dysfunction in atherosclerosis.动脉粥样硬化中的血管僵硬和内皮功能障碍。
Curr Opin Lipidol. 2022 Dec 1;33(6):353-363. doi: 10.1097/MOL.0000000000000852. Epub 2022 Oct 21.
5
In-Hospital Blood Pressure Variability: A Novel Prognostic Marker of Renal Function Decline and Cardiovascular Events in Patients with Coronary Artery Disease.住院期间血压变异性：冠心病患者肾功能下降和心血管事件的新预后标志物。
Kidney Blood Press Res. 2020;45(5):748-757. doi: 10.1159/000509291. Epub 2020 Oct 7.
6
Blood pressure variability: its relevance for cardiovascular homeostasis and cardiovascular diseases.血压变异性：对心血管稳态和心血管疾病的意义。
Hypertens Res. 2020 Jul;43(7):609-620. doi: 10.1038/s41440-020-0421-5. Epub 2020 Mar 13.
7
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.在高危患者中实现了目标收缩压（120-140mmHg）下的舒张压和脉压，并取得了心血管结局：ONTARGET 和 TRANSCEND 试验的结果。
Eur Heart J. 2018 Sep 1;39(33):3105-3114. doi: 10.1093/eurheartj/ehy287.
8
Widening Racial Differences in Risks for Coronary Heart Disease.冠心病风险中日益扩大的种族差异。
Circulation. 2018 Mar 13;137(11):1195-1197. doi: 10.1161/CIRCULATIONAHA.117.030564.
9
Seated postural hypotension.坐位性低血压
J Am Soc Hypertens. 2015 Dec;9(12):985-92. doi: 10.1016/j.jash.2015.10.001. Epub 2015 Oct 9.
10
Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction.急性 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后急性左心室功能障碍的处理。
Am Heart J. 2010 Dec;160(6 Suppl):S16-21. doi: 10.1016/j.ahj.2010.10.011.
Zotero 插件